ENTITY
Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY US)

228
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
Refresh
bullishLepu Biopharma
27 Jun 2022 00:39

Lepu Biopharma (2157 HK): Lead Candidate Marching Toward Commercialization; Pipeline Is Progressing

Lepu is preparing for commercialization of pucotenlimab for two indications in China, after approval. The indications targeted by Lepu’s core drug...

Logo
561 Views
Share
29 May 2022 02:51

Bristol-Myers Squibb Company: A String Of FDA Approvals & Other Drivers

Bristol-Myers Squibb Company had a strong start to 2022 with the U.S. FDA having approved the Camzyos or mavacanten, a first-class medicine for...

Logo
41 Views
Share
17 Apr 2022 17:51

Legend Biotech Corp (LEGN US): Carvykti Approval Is the Silver Lining Amid Uncertainty of Delisting

FDA approval of the company’s first drug Carvykti, with initial peak sales opportunity of $1.5 billion should be considered as a buy opportunity,...

Logo
803 Views
Share
13 Apr 2022 20:45

10-Year Treasury Yield Testing 40-Year Resistance; Upgrading Health Care to Overweight

10-year Treas yield $TNX is now testing 40-year downtrend resistance at 2.8-2.82%. If interest rates are to move lower, now would be the time,...

Logo
398 Views
Share
12 Apr 2022 21:37

Innate Immunotherapeutics (ATX AU): 2022 Is Going to Be a Watershed Year

The company is scheduled to start two phase 2 trials for its lead asset, with first results expected in mid-2023. Investors, with high-risk...

Logo
332 Views
Share
x